Search

Displaying results 1811 - 1820 of 5263 in total
  1. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  2. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.

    Synonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
  3. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  4. Drug

    Methionine

    go.drugbank.com/drugs/DB00134
    ApprovedInvestigationalNutraceutical

    A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.

    Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%
  5. Indication

    Insomnia

    go.drugbank.com/conditions/DBCOND0017531
    Drugs: Amitriptyline · Brotizolam · Butabarbital · Cinolazepam · Clotiazepam · Daridorexant +31 more
  6. Drug

    Benzquinamide

    go.drugbank.com/drugs/DB00767
    ApprovedWithdrawn

    The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

  7. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  8. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    It was withdrawn from the United States market in April 1994.

  9. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). … [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  10. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.